Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in China
721 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Beijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Ürümqi, Xiamen, Zhengzhou
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - Phase 1/2Taking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Beijing, Hefei, Jinan, Nanchang, Xiamen, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - No phaseTaking peopleShanghai Clinical Cohort - Esophageal Cancer
- Where
- Shanghai
- People
- 3,500
- Run by
- Shanghai Chest Hospital
See details and how to joinNCT07312526 - Phase 1Taking peopleA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Where
- Chengdu, Dalian, Fuzhou, Shanghai
- Age
- 18 years and over
- People
- 66
- Run by
- Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
See details and how to joinNCT07923214 - Phase 2/3Not yet taking people in ChinaRC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
- Where
- Beijing, Shanghai
- Age
- 18 years and over
- People
- 680
- Run by
- RemeGen Co., Ltd.
See details and how to joinNCT07935369 - Phase 1/2Taking peopleDual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07551362 - Phase 1/2Taking peopleDual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 36
- Run by
- Beijing Biotech
See details and how to joinNCT07622940 - No phaseTaking peopleMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Where
- Shanwei
- Age
- 18 years to 80 years
- People
- 2,000
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07880106 - Phase 2Taking peopleTotal Neoadjuvant Immunotherapy Plus Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Beijing, Guangzhou
- Age
- 18 years and over
- People
- 42
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07933471 - Phase 2Taking peopleNeoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (POLF) for Resectable Locally Advanced Gastric Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 50
- Run by
- Huashan Hospital
See details and how to joinNCT06054906 - Phase 1/2Taking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Beijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - Phase 3Taking peopleA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - Phase 2Taking peoplePerioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Where
- Nanjing
- Age
- 20 years to 80 years
- People
- 114
- Run by
- Jiangsu Cancer Institute & Hospital
See details and how to joinNCT07408609 - Phase 1Not yet taking people in ChinaGK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
- Where
- Shanghai
- Age
- 18 years and over
- People
- 10
- Run by
- Ruijin Hospital
See details and how to joinNCT07923396 - Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Changchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 3Active, not recruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Baoding, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Tianjin, Wuhan, Xining, Zhenngzhou
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - Phase 1Not yet taking people in ChinaA Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Where
- Changsha
- Age
- 18 years and over
- People
- 540 worldwide
- Run by
- Pfizer
See details and how to joinNCT07090499 · EU 2025-521729-33-00 - Phase 2/3Taking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Weihui, Wuhan, Yangzhou, Zhengzhou
- Age
- 18 years and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - Phase 2Taking peopleCandonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Where
- Wuhan
- Age
- 18 years to 75 years
- People
- 59
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07920224 - Phase 1Taking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Beijing, Guangzhou, Shanghai
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Hangzhou, Shanghai
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1Not yet taking people in ChinaA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Beijing, Tianjin
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1Not yet taking people in ChinaA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Where
- Shanghai
- Age
- 18 years and over
- People
- 340 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00 - No phaseTaking peopleRemimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
- Where
- Nanjing
- Age
- 65 years to 100 years
- People
- 170
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07351474 - Phase 1Not yet taking people in ChinaSND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
- Where
- Guiyang, Hangzhou
- Age
- 18 years to 80 years
- People
- 78
- Run by
- Guizhou Sinorda Pharmaceutical Co., Ltd.
See details and how to joinNCT07903857